{"analyses":[{"ciLowerLimit":"0.534","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.793","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.651","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Here NA signifies that the upper limit of CI was not estimable due to lesser number of events.","groupId":"OG000","lowerLimit":"41.86","upperLimit":"NA","value":"52.17"},{"comment":"Here NA signifies that the median, lower limit and upper limit of CI were not estimable due to lesser number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"527"},{"groupId":"OG001","value":"525"}],"units":"Participants"}],"description":"OS was defined as the time from date of randomization to date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received matching placebo (4 tablets) orally once daily (qd) along with ADT (gonadotropin releasing hormone analog \\[GnRHa\\] or surgical castration) as standard of care therapy in each 28-day treatment cycle. The choice of the GnRHa (agonist or antagonist) was at discretion of the investigator. In the event of a positive result at interim or final analysis participants in treatment phase had opportunity to receive Apalutamide +ADT. Participants received treatment until radiographic progression or unequivocal clinical progression, unacceptable toxicity, or death.","id":"OG000","title":"Placebo + Androgen Deprivation Therapy (ADT)"},{"description":"Participants received JNJ-56021927 (apalutamide) 240 milligrams (mg) (4\\*60 mg tablets) orally qd along with ADT (gonadotropin releasing hormone analog \\[GnRHa\\] or surgical castration) as standard of care therapy in each 28-day treatment cycle. The choice of the GnRHa (agonist or antagonist) was at discretion of the investigator. Participants received treatment until radiographic progression or unequivocal clinical progression, unacceptable toxicity, or death.","id":"OG001","title":"Apalutamide + ADT"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 57 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}